Maximizing the Benefit-Cost Ratio of Anthracyclines in Metas
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Anthracyclines, such as doxorubicin (adriamycin), are a class of drugs that have been used in cancer chemotherapy regimens in a large number of tumor types since their discovery in the 1970s.Despite the clinical efficacy of anthracycline agents such as doxorubicin, dose-limiting cardiac toxicities significantly limit their long-term use. Here, we present the case of a 33-year-old female patient with extensive metastatic ER+/PR+/HER2– mucinous adenocarcinoma of the breast, who was started on doxorubicin/cyclophosphamide therapy after progressing on paclitaxel and ovarian suppressor goserelin with aromatase inhibitor exemestane. ....

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216250/
Like
Comment
Share